Skip to main content

Advertisement

SpringerLink
Log in

Time Trends in Healthcare Utilization Due to Self-Reported Functional Diseases of the Stomach

  • Original Article
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Introduction

Cohort studies from referral centers suggest an increasing burden of functional gastric disorders, with frequent emergency room (ER) visits, hospitalizations, or absenteeism. We hypothesized that recruitment from tertiary care sites skews results and thus investigated the burden of these illnesses, using the population-based data of the Medical Expenditure Panel Survey (MEPS).

Methods

Using MEPS data for the years 2000–2015, demographic, economic, healthcare-related, and quality-of-life indicators were extracted for adults reporting the diagnosis of functional gastric diseases to assess trends and to compare results with data from all adults surveyed.

Results

Between 2000 and 2015, 2.7 ± 0.2% of the adults surveyed reported a functional gastric illness. Within the period studied, 28.8 ± 2.8% and 17.9 ± 1.6% of this cohort reported ER visits or hospitalizations, respectively. Only a fraction of these persons attributed the ER visits (22.6 ± 0.9%) or admissions (10.9 ± 0.8%) to the functional gastric disorder. Rates remained stable rates during the period studied. Female sex, measures of physical function, comorbidities, and an income below the poverty line were predictors of healthcare utilization. While utilization was stable over time, annual costs increased by 113.9 ± 16.6% during the study period, outpacing the inflation rate of 37.6%.

Conclusions

Persons with functional gastric disorders have significant healthcare needs and face increasing costs of care, largely due to coexisting illnesses. While it is important to recognize this impact, the need for emergency care or hospitalizations remained stable and lower than reported for patients seen in tertiary referral centers, providing reassuring information for patients and providers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Olafsdottir LB, Gudjonsson H, Jonsdottir HH, et al. Natural history of functional gastrointestinal disorders: comparison of two longitudinal population-based studies. Dig Liver Dis. 2012;44:211–217.

    PubMed  Google Scholar 

  2. Olafsdottir L, Gudjonsson H, Jonsdottir H, et al. Natural history of functional dyspepsia: a 10-year population-based study. Digestion. 2010;81:53–61.

    PubMed  Google Scholar 

  3. Tack J, Caenepeel P, Fischler B, et al. Symptoms associated with hypersensitivity to gastric distention in functional dyspepsia. Gastroenterology. 2001;121:526–535.

    PubMed  CAS  Google Scholar 

  4. Van Oudenhove L, Vandenberghe J, Geeraerts B, et al. Determinants of symptoms in functional dyspepsia: gastric sensorimotor function, psychosocial factors or somatisation? Gut. 2008;57:1666–1673.

    PubMed  Google Scholar 

  5. Vanheel H, Carbone F, Valvekens L, et al. Pathophysiological abnormalities in functional dyspepsia subgroups according to the Rome III criteria. Am J Gastroenterol. 2017;112:132–140.

    PubMed  CAS  Google Scholar 

  6. Stanghellini V, Tack J. Gastroparesis: separate entity or just a part of dyspepsia? Gut. 2014;63:1972–1978.

    PubMed  Google Scholar 

  7. Pasricha PJ, Colvin R, Yates K, et al. Characteristics of patients with chronic unexplained nausea and vomiting and normal gastric emptying. Clin Gastroenterol Hepatol. 2011;9:567–576.

    PubMed  PubMed Central  Google Scholar 

  8. Parkman HP, Yates K, Hasler WL, et al. Clinical features of idiopathic gastroparesis vary with sex, body mass, symptom onset, delay in gastric emptying, and gastroparesis severity. Gastroenterology. 2011;140:101–115.

    PubMed  Google Scholar 

  9. Parkman HP, Yates K, Hasler WL, et al. Similarities and differences between diabetic and idiopathic gastroparesis. Clin Gastroenterol Hepatol. 2011;9:1056–1064.

    PubMed  Google Scholar 

  10. Koch KL, Hasler WL, Yates KP, et al. Baseline features and differences in 48 week clinical outcomes in patients with gastroparesis and type 1 vs type 2 diabetes. Neurogastroenterol Motil. 2016;28:1001–1015.

    PubMed  PubMed Central  CAS  Google Scholar 

  11. Parkman HP, Yamada G, Van Natta ML, et al. Ethnic, racial, and sex differences in etiology, symptoms, treatment, and symptom outcomes of patients with gastroparesis. Clin Gastroenterol Hepatol. 2018;17:1489–1499.

    PubMed  PubMed Central  Google Scholar 

  12. Dudekula A, O’Connell M, Bielefeldt K. Hospitalizations and testing in gastroparesis. J Gastroenterol Hepatol. 2011;26:1275–1282.

    PubMed  Google Scholar 

  13. Dudekula A, Rahim S, Bielefeldt K. Time trends in gastroparesis treatment. Dig Dis Sci. 2014;59:2656–2665. https://doi.org/10.1007/s10620-014-3369-y.

    Article  PubMed  Google Scholar 

  14. Nusrat S, Bielefeldt K. Gastroparesis on the rise: incidence vs awareness? Neurogastroenterol Motil. 2013;25:16–22.

    PubMed  CAS  Google Scholar 

  15. Wang YR, Fisher RS, Parkman HP. Gastroparesis-related hospitalizations in the United States: trends, characteristics, and outcomes, 1995–2004. Am J Gastroenterol. 2008;103:313–322.

    PubMed  Google Scholar 

  16. Hurst N, Ruta D, Kind P. Comparison of the MOS short form-12 (SF12) health status questionnaire with the SF36 in patients with rheumatoid arthritis. Rheumatology. 1998;37:862–869.

    CAS  Google Scholar 

  17. Cutts TF, Luo J, Starkebaum W, et al. Is gastric electrical stimulation superior to standard pharmacologic therapy in improving GI symptoms, healthcare resources, and long-term health care benefits? Neurogastroenterol Motil. 2005;17:35–43.

    PubMed  CAS  Google Scholar 

  18. Hasler WL, Wilson LA, Nguyen LA, et al. Opioid use and potency are associated with clinical features, quality of life, and use of resources in patients with gastroparesis. Clin Gastroenterol Hepatol. 2019;17:1285–1294.

    PubMed  CAS  Google Scholar 

  19. Uppalapati SS, Ramzan Z, Fisher RS, et al. Factors contributing to hospitalization for gastroparesis exacerbations. Dig Dis Sci. 2009;54:2404–2409. https://doi.org/10.1007/s10620-009-0975-1.

    Article  PubMed  Google Scholar 

  20. Hejazi RA, Reddymasu SC, Namin F, et al. Efficacy of tricyclic antidepressant therapy in adults with cyclic vomiting syndrome: a two-year follow-up study. J Clin Gastroenterol. 2010;44:18–21.

    PubMed  Google Scholar 

  21. Prakash C, Staiano A, Rothbaum RJ, et al. Similarities in cyclic vomiting syndrome across age groups. Am J Gastroenterol. 2001;96:684–688.

    PubMed  CAS  Google Scholar 

  22. Venkatesan T, Tarbell S, Adams K, et al. A survey of emergency department use in patients with cyclic vomiting syndrome. BMC Emerg Med. 2010;10:4.

    PubMed  PubMed Central  Google Scholar 

  23. Hungin AP, Hill C, Raghunath A. Systematic review: frequency and reasons for consultation for gastro-oesophageal reflux disease and dyspepsia. Aliment Pharmacol Ther. 2009;30:331–342.

    PubMed  CAS  Google Scholar 

  24. Piessevaux H, de Winter B, Louis E, et al. Dyspeptic symptoms in the general population: a factor and cluster analysis of symptom groupings. Neurogastroenterol Motil. 2009;21:378–388.

    PubMed  CAS  Google Scholar 

  25. Lacy BE, Weiser KT, Kennedy AT, et al. Functional dyspepsia: the economic impact to patients. Aliment Pharmacol Ther. 2013;38:170–177.

    PubMed  CAS  Google Scholar 

  26. Kurata JH, Nogawa AN, Everhart JE. A prospective study of dyspepsia in primary care. Dig Dis Sci. 2002;47:797–803. https://doi.org/10.1023/A:1014748202229.

    Article  PubMed  CAS  Google Scholar 

  27. Brook RA, Kleinman NL, Choung RS, et al. Functional dyspepsia impacts absenteeism and direct and indirect costs. Clin Gastroenterol Hepatol. 2010;8:498–503.

    PubMed  Google Scholar 

  28. Mapel D, Roberts M, Overhiser A, et al. The epidemiology, diagnosis, and cost of dyspepsia and Helicobacter pylori gastritis: a case-control analysis in the Southwestern United States. Helicobacter. 2013;18:54–65.

    PubMed  Google Scholar 

  29. Johansson PA, Farup PG, Bracco A, et al. How does comorbidity affect cost of health care in patients with irritable bowel syndrome? a cohort study in general practice. BMC Gastroenterol. 2010;10:31.

    PubMed  PubMed Central  Google Scholar 

  30. Alander T, Svardsudd K, Agreus L. Functional gastrointestinal disorder is associated with increased non-gastrointestinal healthcare consumption in the general population. Int J Clin Pract. 2008;62:234–240.

    PubMed  PubMed Central  CAS  Google Scholar 

  31. Whitehead W, Palsson O, Jones K. Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? Gastroenterology. 2002;122:1140–1156.

    PubMed  Google Scholar 

  32. Williams RE, Black CL, Kim H-Y, et al. Determinants of healthcare-seeking behaviour among subjects with irritable bowel syndrome. Aliment Pharmacol Ther. 2006;23:1667–1675.

    PubMed  CAS  Google Scholar 

  33. Ozieh MN, Bishu KG, Dismuke CE, et al. Trends in health care expenditure in US adults with diabetes: 2002–2011. Diabetes Care. 2015;38:1844–1851.

    PubMed  PubMed Central  Google Scholar 

  34. Echouffo-Tcheugui JB, Bishu KG, Fonarow GC, et al. Trends in health care expenditure among US adults with heart failure: the Medical Expenditure Panel Survey 2002–2011. Am Heart J. 2017;186:63–72.

    PubMed  PubMed Central  Google Scholar 

  35. McKercher PL, Taylor SD, Lee JA, et al. Prescription drug use among elderly and nonelderly families. J Manag Care Pharm. 2003;9:19–28.

    PubMed  Google Scholar 

  36. Gellad WF, Donohue JM, Zhao X, et al. The financial burden from prescription drugs has declined recently for the nonelderly, although it is still high for many. Health Aff (Millwood). 2012;31:408–416.

    PubMed  PubMed Central  Google Scholar 

  37. Yu H, MacIsaac D, Wong JJ, et al. Market share and costs of biologic therapies for inflammatory bowel disease in the USA. Aliment Pharmacol Ther. 2018;47:364–370.

    PubMed  CAS  Google Scholar 

  38. Rodwin BA, Salami JA, Spatz ES, et al. Variation in the use of warfarin and direct oral anticoagulants in atrial fibrillation and associated cost implications. Am J Med. 2019;132:61–70.

    PubMed  CAS  Google Scholar 

  39. Atzinger CB, Guo JJ. Biologic disease-modifying antirheumatic drugs in a national, privately insured population: utilization, expenditures, and price trends. Am Health Drug Benefits. 2017;10:27–36.

    PubMed  PubMed Central  Google Scholar 

  40. Mukherjee K, Kamal KM. Sociodemographic determinants of out-of-pocket expenditures for patients using prescription drugs for rheumatoid arthritis. Am Health Drug Benefits. 2017;10:7–15.

    PubMed  PubMed Central  Google Scholar 

  41. Lacy BE, Crowell MD, Mathis C, et al. Gastroparesis: quality of life and health care utilization. J Clin Gastroenterol. 2018;52:20–24.

    PubMed  Google Scholar 

  42. Jehangir A, Parkman HP. Chronic opioids in gastroparesis: relationship with gastrointestinal symptoms, healthcare utilization and employment. World J Gastroenterol. 2017;23:7310–7320.

    PubMed  PubMed Central  Google Scholar 

  43. Agreus L, Borgquist L. The cost of gastro-oesophageal reflux disease, dyspepsia and peptic ulcer disease in Sweden. Pharmacoeconomics. 2002;20:347–355.

    PubMed  Google Scholar 

  44. Westbrook JI, Talley NJ, Westbrook MT. Gender differences in the symptoms and physical and mental well-being of dyspeptics: a population based study. Qual Life Res. 2002;11:283–291.

    PubMed  Google Scholar 

  45. Bielefeldt K, Raza N, Zickmund SL. Different faces of gastroparesis. World J Gastroenterol. 2009;15:6052–6060.

    PubMed  PubMed Central  Google Scholar 

  46. Hasler WL, Wilson LA, Parkman HP, et al. Factors related to abdominal pain in gastroparesis: contrast to patients with predominant nausea and vomiting. Neurogastroenterol Motil. 2013;25:427-e301.

    Google Scholar 

  47. Jacobson BC, Ferris TG, Shea TL, et al. Who is using chronic acid suppression therapy and why? Am J Gastroenterol. 2003;98:51–58.

    PubMed  Google Scholar 

  48. Choung RS, Locke GR, Schleck CD, et al. Associations between medication use and functional gastrointestinal disorders: a population-based study. Neurogastroenterol Motil. 2013;25:413-e298.

    PubMed Central  Google Scholar 

  49. Pottegard A, Broe A, Hallas J, et al. Use of proton-pump inhibitors among adults: a Danish nationwide drug utilization study. Therap Adv Gastroenterol. 2016;9:671–678.

    PubMed  PubMed Central  Google Scholar 

  50. Miller GE, Moriya AS. Any Use and Frequent Use of Opioids Among Non-elderly Adults in 2015–2016, By Socioeconomic Characteristics Statistical Brief #516, vol. 2019. Rockville, MD: Agency for Healthcare Research and Quality; 2018.

    Google Scholar 

  51. Moriya AS, Miller GE. Any Use and Frequent Use of Opioids Among Elderly Adults in 2015–2016, By Socioeconomic Characteristics. Statistical Brief #515. Rockville, MD: Agency for Healthcare Research and Quality; 2019:2018.

    Google Scholar 

  52. Coleski R, Anderson M, Hasler W. Factors associated with symptom response to pyloric injection of botulinum toxin in a large series of gastroparesis patients. Dig Dis Sci. 2009;54:2634–2642. https://doi.org/10.1007/s10620-008-0660-9.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Gastroenterology, George E. Wahlen VA Medical Center, 500 Foothill Dr, Salt Lake City, UT, 84148, USA

    Klaus Bielefeldt

  2. University of Utah, Salt Lake City, USA

    Klaus Bielefeldt

Authors
  1. Klaus Bielefeldt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Klaus Bielefeldt.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 13 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bielefeldt, K. Time Trends in Healthcare Utilization Due to Self-Reported Functional Diseases of the Stomach. Dig Dis Sci 65, 2824–2833 (2020). https://doi.org/10.1007/s10620-020-06154-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-020-06154-0

Keywords

Search

Navigation